DexCom, Inc. (NASDAQ:DXCM) Shares Purchased by Patten & Patten Inc. TN

Patten & Patten Inc. TN boosted its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 5.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 74,811 shares of the medical device company's stock after buying an additional 3,570 shares during the period. Patten & Patten Inc. TN's holdings in DexCom were worth $5,818,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of DXCM. Versant Capital Management Inc purchased a new position in DexCom in the 4th quarter valued at $25,000. Private Trust Co. NA grew its position in DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after buying an additional 245 shares during the last quarter. Larson Financial Group LLC grew its position in DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after buying an additional 137 shares during the last quarter. Heck Capital Advisors LLC purchased a new position in DexCom in the 4th quarter valued at $38,000. Finally, SBI Securities Co. Ltd. purchased a new position in DexCom in the 4th quarter valued at $49,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Jereme M. Sylvain sold 2,090 shares of the company's stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares of the company's stock, valued at $7,259,244.66. This represents a 2.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Kevin R. Sayer sold 32,498 shares of the company's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the transaction, the chief executive officer now directly owns 372,029 shares of the company's stock, valued at approximately $26,183,401.02. This represents a 8.03 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 105,009 shares of company stock valued at $8,044,178 in the last 90 days. 0.30% of the stock is currently owned by insiders.

Remove Ads

DexCom Price Performance

DXCM stock traded up $1.73 during trading on Thursday, hitting $75.11. The stock had a trading volume of 3,588,241 shares, compared to its average volume of 3,891,676. The company's 50 day moving average price is $83.51 and its two-hundred day moving average price is $76.93. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The stock has a market cap of $29.35 billion, a price-to-earnings ratio of 52.52, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, sell-side analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

DXCM has been the topic of a number of analyst reports. Baird R W upgraded shares of DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Robert W. Baird upgraded shares of DexCom from a "neutral" rating to an "outperform" rating and boosted their target price for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. Citigroup boosted their target price on shares of DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a research report on Tuesday, March 4th. Finally, Canaccord Genuity Group boosted their target price on shares of DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a research report on Friday, February 14th. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $99.82.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.